GET THE APP

Role of 2-DG in Fighting COVID-19 | Abstract

Journal of Research in Medical and Dental Science
eISSN No. 2347-2367 pISSN No. 2347-2545

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Role of 2-DG in Fighting COVID-19

Author(s): Nilay Krishna*, Abhishek Ingole

Abstract

A new respiratory pathogen, SARS-CoV-2, is now a global hobby and has been declared a global public health emergency. Invasion of SARS-CoV-2 is mediated by viral spike glycoprotein (S2). The virus is then conserved from the host cell machine by using the number one viral proteases 3CLpro and NSP15 endoribonuclease. In the popular context, a review of modified virulence factors with the help of a unique chemotherapeutic drug as a promising new anti-cancer drug and a new 2DG analog dose adjuvant called this review. The causes of the modern COVID-19 pandemic have been extensively studied to analyse its pathophysiology and its effects on metabolic tools in human cells. Glycolysis copies and spreads the virus as energy. Therefore, interrupting viral replication helps reduce viral replication. The idea behind reusing it in COVID-19 is that 2DG can be combined with certain antivirals to prevent the replication of SARS-CoV-2 virus in inflamed lung cells in COVID-19 patients.

In addition, SARS-CoV-2 was found to be approximately 96.2% similar to the bat CoV-2 RaTG13, suggesting that bats are the natural reservoir of this virus. As a result, human to human transmission of the infection began through direct contact with the infected person and through respiratory droplets In addition, some studies have shown that SARS-CoV-2 may be in the faeces of infected people, or perhaps after the affected personality has healed, suggesting a faecal orientation for viral infections. COVID-19's current recovery management is particularly supportive care (WHO Interim Guidance 2020). However, antiviral distributors such as remdesivir, lopinavir alone, and a mixture of interferon and ribavirin have been evaluated with limited success.

Share this article